Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
www.forbes.com
August 26, 2026 at 3:55 PM
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
A drug recently approved for the treatment of metastatic pancreatic cancer, is also showing promise in the treatment of lung cancer.
www.medicalnewstoday.com/articles/pan...
www.medicalnewstoday.com/articles/pan...
Lung cancer: Drug approved by FDA for pancreatic cancer may help
Daraxonrasib (Rasonque), recently approved for the treatment of metastatic pancreatic cancer, is also showing promise in the treatment of lung cancer in early trials.
www.medicalnewstoday.com
September 12, 2026 at 3:00 AM
A drug recently approved for the treatment of metastatic pancreatic cancer, is also showing promise in the treatment of lung cancer.
www.medicalnewstoday.com/articles/pan...
www.medicalnewstoday.com/articles/pan...
This is exceptional news for patients with this devastating disease. Rasonque is likely to be used in many other tumors where the protooncogene KRas is mutated (lung cancer, colon cancer, and others).
#Science 🧪
#Science 🧪
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced ...
www.fda.gov
August 26, 2026 at 4:27 PM
This is exceptional news for patients with this devastating disease. Rasonque is likely to be used in many other tumors where the protooncogene KRas is mutated (lung cancer, colon cancer, and others).
#Science 🧪
#Science 🧪
FDA approved Rasonque for metastatic pancreatic cancer. This oral drug targets the RAS protein, long thought 'undruggable.' In trials, 500 patients with widespread disease saw median survival almost double, from 6.7 to 13.2 months.
FDA Approves First Oral RAS Inhibitor, Rasonque, for Metastatic Pancreatic Cancer, Nearly Doubling P
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib (brand name Rasonque), a pioneering oral drug targeting the RAS protein, for adults with metastatic pancreatic adenocarcinoma. Thi
www.nationalgeographic.com
August 30, 2026 at 2:02 PM
FDA approved Rasonque for metastatic pancreatic cancer. This oral drug targets the RAS protein, long thought 'undruggable.' In trials, 500 patients with widespread disease saw median survival almost double, from 6.7 to 13.2 months.
The FDA approves a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
FDA approves ‘game-changing’ pancreatic cancer drug
In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care.
nbcnews.to
August 31, 2026 at 8:00 AM
The FDA approves a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
The approval covers patients with metastatic disease who progressed after a first-line treatment, a group of approximately 19,000 people per year just in the United States.
Rasonque Hits the Market: FDA Approves First RAS(ON) Inhibitor for Most Deadly Pancreatic Tumor - Sinaptica
The United States Food and Drug Administration approved on August 26, 2026 Rasonque (generic name daraxonrasib), the first multiselective RAS(ON) inhibitor auth
sinapti.ca
August 30, 2026 at 7:11 PM
The approval covers patients with metastatic disease who progressed after a first-line treatment, a group of approximately 19,000 people per year just in the United States.
The FDA has approved a drug that slows pancreatic cancer, a breakthrough treatment for a disease that kills seven out of eight patients within five years.
www.semafor.com/article/08/2...
www.semafor.com/article/08/2...
FDA approves breakthrough drug for pancreatic cancer treatment
In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as those who only received chemotherapy.
www.semafor.com
August 27, 2026 at 4:35 PM
The FDA has approved a drug that slows pancreatic cancer, a breakthrough treatment for a disease that kills seven out of eight patients within five years.
www.semafor.com/article/08/2...
www.semafor.com/article/08/2...
The FDA approves a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
FDA approves ‘game-changing’ pancreatic cancer drug
In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care.
nbcnews.to
August 26, 2026 at 11:00 PM
The FDA approves a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
A new pancreatic cancer drug doubled patients’ average survival times, the FDA said.
Researchers have called the drug, known as Rasonque or daraxonrasib, a “landmark” development for one of the deadliest cancers.
Researchers have called the drug, known as Rasonque or daraxonrasib, a “landmark” development for one of the deadliest cancers.
FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
www.washingtonpost.com
August 27, 2026 at 2:00 AM
A new pancreatic cancer drug doubled patients’ average survival times, the FDA said.
Researchers have called the drug, known as Rasonque or daraxonrasib, a “landmark” development for one of the deadliest cancers.
Researchers have called the drug, known as Rasonque or daraxonrasib, a “landmark” development for one of the deadliest cancers.
FDA Approves New Pancreatic Cancer Pill Rasonque, Priced At Nearly $480,000 A Year. Rasonque Could Extend Patients' Lives By About Six Months Compared To Chemotherapy.
Hundreds Of People In Detroit Were Fooled By A Fake Grocery Store Giveaway After An AI-Generated Flyer Went Viral On Facebook.
Hundreds Of People In Detroit Were Fooled By A Fake Grocery Store Giveaway After An AI-Generated Flyer Went Viral On Facebook.
September 5, 2026 at 1:53 AM
FDA Approves New Pancreatic Cancer Pill Rasonque, Priced At Nearly $480,000 A Year. Rasonque Could Extend Patients' Lives By About Six Months Compared To Chemotherapy.
Hundreds Of People In Detroit Were Fooled By A Fake Grocery Store Giveaway After An AI-Generated Flyer Went Viral On Facebook.
Hundreds Of People In Detroit Were Fooled By A Fake Grocery Store Giveaway After An AI-Generated Flyer Went Viral On Facebook.
When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied. www.statnews.com/2026/09/08/p...
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied.
www.statnews.com
September 8, 2026 at 2:02 PM
When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied. www.statnews.com/2026/09/08/p...
A new pancreatic cancer drug costs $480,000 a year, or $663 a tablet. The treatment, from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
nyti.ms
August 31, 2026 at 10:25 PM
A new pancreatic cancer drug costs $480,000 a year, or $663 a tablet. The treatment, from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
Weeks later, patients who urgently need the drug are caught between regulatory approval and insurance responses, according to an investigation by STAT News .
Rasonque approved for pancreatic cancer, but patients face issues with insurers - Sinaptica
The FDA approved in August 2026 Rasonque (daraxonrasib), the first RAS(ON) inhibitor for metastatic pancreatic cancer. Weeks later, patients who urgently need t
sinapti.ca
September 8, 2026 at 9:32 AM
Weeks later, patients who urgently need the drug are caught between regulatory approval and insurance responses, according to an investigation by STAT News .
Die FDA genehmigt die erste zielgerichtete Therapie für metastasierten Bauchspeicheldrüsenkrebs
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced ...
www.fda.gov
August 27, 2026 at 10:37 AM
Die FDA genehmigt die erste zielgerichtete Therapie für metastasierten Bauchspeicheldrüsenkrebs
FDA approves new drug Rasonque to treat advanced pancreatic cancer
FDA approves new drug Rasonque to treat advanced pancreatic cancer
The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily pill doubled survival rates, offering fresh hope for people who have exhausted other treatments.
f24.my
August 26, 2026 at 11:12 PM
FDA approves new drug Rasonque to treat advanced pancreatic cancer
new fda-approved rasonque targets kras, a protein driving most pancreatic cancers, previously "undruggable." for 500 previously treated patients, it meant 13.2 months survival vs. 6.7 with chemo. a real shift for a tough disease.
August 26, 2026 at 8:04 PM
new fda-approved rasonque targets kras, a protein driving most pancreatic cancers, previously "undruggable." for 500 previously treated patients, it meant 13.2 months survival vs. 6.7 with chemo. a real shift for a tough disease.
Se aprueba daraxonrasib, un nuevo tratamiento dirigido contra el cáncer
de páncreas www.imfarmacias.es/noticia/4251...
de páncreas www.imfarmacias.es/noticia/4251...
Se aprueba daraxonrasib un nuevo tratamiento dirigido contra el cáncer
de páncreas
La Administración de Alimentos y Medicamentos de Estados Unidos FDA por sus siglas en inglés ha aprobado daraxonrasib Rasonque
www.imfarmacias.es
August 31, 2026 at 6:38 AM
Se aprueba daraxonrasib, un nuevo tratamiento dirigido contra el cáncer
de páncreas www.imfarmacias.es/noticia/4251...
de páncreas www.imfarmacias.es/noticia/4251...
Les États-Unis approuvent le Rasonque, un traitement prometteur contre le cancer du pancréas
Les États-Unis approuvent le Rasonque, un traitement prometteur contre le cancer du pancréas
Les États-Unis ont approuvé mercredi un médicament, le Rasonque, considéré par les experts comme l'avancée la plus significative jamais connue dans la lutte contre le cancer du pancréas. Ce traitement en comprimés permettra d'allonger la durée de vie des malades.
f24.my
August 26, 2026 at 10:19 PM
Les États-Unis approuvent le Rasonque, un traitement prometteur contre le cancer du pancréas
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer, delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
#Blues
#Blues
This is exceptional news for patients with this devastating disease. Rasonque is likely to be used in many other tumors where the protooncogene KRas is mutated (lung cancer, colon cancer, and others).
#Science 🧪
#Science 🧪
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced ...
www.fda.gov
August 27, 2026 at 3:24 AM
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer, delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
#Blues
#Blues
Le Rasonque a montré des résultats très encourageants en doublant la durée de survie des malades de cette forme de cancer très agressive. Après le feu vert de l’agence américaine du médicament, celui de son homologue européenne pourrait suivre.
➡️ https://l.liberation.fr/rmC
➡️ https://l.liberation.fr/rmC
August 27, 2026 at 11:30 PM
Le Rasonque a montré des résultats très encourageants en doublant la durée de survie des malades de cette forme de cancer très agressive. Après le feu vert de l’agence américaine du médicament, celui de son homologue européenne pourrait suivre.
➡️ https://l.liberation.fr/rmC
➡️ https://l.liberation.fr/rmC
The FDA has approved Rasonque, a new targeted treatment for metastatic pancreatic cancer. In a 500-patient trial, median survival was 13.2 months with the drug versus 6.7 months with standard chemotherapy. #Cancer #FDA
www.france24.com/en/americas/...
www.france24.com/en/americas/...
FDA approves new drug Rasonque to treat advanced pancreatic cancer
The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily…
www.france24.com
August 27, 2026 at 11:16 AM
The FDA has approved Rasonque, a new targeted treatment for metastatic pancreatic cancer. In a 500-patient trial, median survival was 13.2 months with the drug versus 6.7 months with standard chemotherapy. #Cancer #FDA
www.france24.com/en/americas/...
www.france24.com/en/americas/...
The FDA just approved Rasonque (daraxonrasib), a new RAS inhibitor that nearly doubled median survival in clinical trials, from about 6–7 months with standard chemotherapy to more than 13 months.
What should patients know? Dr. Paul Hanona breaks it down.
What should patients know? Dr. Paul Hanona breaks it down.
August 27, 2026 at 7:00 PM
The FDA just approved Rasonque (daraxonrasib), a new RAS inhibitor that nearly doubled median survival in clinical trials, from about 6–7 months with standard chemotherapy to more than 13 months.
What should patients know? Dr. Paul Hanona breaks it down.
What should patients know? Dr. Paul Hanona breaks it down.
THIS is the disgusting part: "The new FDA-approved pancreatic cancer drug Rasonque (daraxonrasib) by Revolution Medicines has a list price of $39,800 per month, which equals about $663 per pill or roughly $477,000 to $480,000 per year."
September 3, 2026 at 12:45 AM
THIS is the disgusting part: "The new FDA-approved pancreatic cancer drug Rasonque (daraxonrasib) by Revolution Medicines has a list price of $39,800 per month, which equals about $663 per pill or roughly $477,000 to $480,000 per year."
Développé par la start-up américaine Revolution Medicines, ce médicament est nommé Rasonque et pourra être pris sous la forme de comprimés .
Les Etats-Unis approuvent un traitement prometteur contre le cancer du pancréas
l.franceinfo.fr
August 26, 2026 at 10:25 PM
Développé par la start-up américaine Revolution Medicines, ce médicament est nommé Rasonque et pourra être pris sous la forme de comprimés .